

## Special Issue

# Genetic Markers in Targeted Therapies: From Biomarker Discovery to Personalized Therapy

### Message from the Guest Editor

Molecular markers play a crucial role in targeted therapies, as they enable treatment to be targeted to a patient's individual genetic characteristics. They not only enable more effective treatment of diseases, but also facilitate their prevention and early detection, significantly improving patients' quality of life and prognosis. Similarly, the integration of multi-omics data (genomics, transcriptomics) with functional studies in cell culture models has elucidated the roles of genomic instability, cellular senescence, and chromosomal dynamics in cancer progression and therapy resistance. In this Special Issue of *Genes*, we invite authors to submit review and research articles on molecular markers in terms of their use for early disease detection as well as disease prognosis and monitoring of response to therapy. In addition, we are interested in scientific articles on understanding disease mechanisms at the molecular level and identifying molecular markers for the development of new, targeted therapies, including theranostics.

---

### Guest Editor

Dr. Maciej Wnuk

Faculty of Biotechnology, Collegium Medicum, University of Rzeszow, 1 Pigonia St., 35-310 Rzeszów, Poland

---

### Deadline for manuscript submissions

closed (15 March 2026)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/253280](https://mdpi.com/si/253280)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))